-
Ligand Signs Global License Deal with Azure for Lasofoxifene
Monday, July 22, 2013 - 8:32am | 80Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health. Under the terms of the agreement, Ligand is entitled to receive $2....
-
Metabolix Announces Promotion of Johan van Walsem to Chief Operating Officer
Wednesday, July 17, 2013 - 4:05pm | 448Metabolix (NASDAQ: MBLX), an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries, announced today that Johan van Walsem has been promoted to the position of Chief Operating Officer (COO), effective Monday, July 22. In this newly...
-
Morning Market Movers
Monday, July 8, 2013 - 10:03am | 107Prime Acquisition (NASDAQ: PACQ) rose 63.66% to $16.35. Prime Acquisition shares have gained 3.63% over the past 52 weeks, while the S&P 500 index has gained 20.66% in the same period. Luna Innovations (NASDAQ: LUNA) shares jumped 56.92% to $2.04 after the company announced a multi-year...
-
Luna Innovations, Intuitive Surgical Announce Multi-Year Deal
Monday, July 8, 2013 - 9:01am | 138Luna Innovations Incorporated (NASDAQ: LUNA), which develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets, today announced a multi-year agreement that amends its development and supply agreement with Intuitive Surgical, Inc., (NASDAQ:...
-
Benzinga's Volume Movers
Monday, July 1, 2013 - 10:44am | 156Onyx Pharmaceuticals (NASDAQ: ONXX) surged 50.91% to $131.02. The volume of Onyx Pharmaceuticals shares traded was 2615% higher than normal. Onyx rejected a takeover offer from Amgen (NASDAQ: AMGN) for $120 per share. Novo Nordisk A/S (NYSE: NVO) shares moved up 2.23% to $158.42. The volume of...
-
Ligand Pharma Announces Preclinical Data for Glucagon Program
Monday, June 24, 2013 - 8:34am | 224Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the presentation of a poster titled “Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice” at the 73^rd Scientific Sessions of the American Diabetes Association in Chicago. The poster provides data...
-
Lexicon Pharma Issues Preclincial Data on LX2761
Monday, June 24, 2013 - 8:06am | 308Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented the first publication of data on LX2761 at the 73^rd Scientific Sessions of the American Diabetes Association (ADA) in Chicago, on June 23, 2013....
-
Ligand Pharma Boosts Ownership Limit for BVF to 25% of Outstanding Shares
Thursday, June 20, 2013 - 8:32am | 263Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its Board of Directors has agreed to waive certain “poison pill” provisions to allow BVF Partners L.P., including its affiliates and associates (“BVF”), to increase its ownership of the Company from the previous limit of 19.99% of...
-
Maxygen Announces Board Decision to Dissolve the Company
Monday, June 3, 2013 - 9:01am | 1689Maxygen (Nasdaq: MAXY), a biopharmaceutical company, today announced that its Board of Directors has approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known...
-
Ligand Partner Rib-X Initiates Phase 3 Trial of Captisol-enabled™ Delafloxacin IV
Tuesday, May 14, 2013 - 8:33am | 1031Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Rib-X Pharmaceuticals, Inc. has initiated a Phase 3 clinical trial of a Captisol-enabled™ intravenous (IV) formulation of delafloxacin for the first-line treatment of acute bacterial skin and skin structure...
-
Lexicon Issues Update on Phase 2 Trial of LX4211 In Type 1 Diabetes
Friday, May 10, 2013 - 6:10am | 213Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial. LX4211 is an...
-
Ligand Announces $5M Buyback, Q1 Earnings
Wednesday, May 8, 2013 - 4:14pm | 2092Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the first quarter ended March 31, 2013, and provided an operating forecast and program updates. “We have had an excellent start to 2013 and are excited about how quickly the company is evolving into a...
-
Stocks Hitting 52-Week Highs
Monday, April 22, 2013 - 10:34am | 141Ligand Pharmaceuticals (NASDAQ: LGND) shares touched a new 52-week high of $27.71. Ligand is expected to report its Q1 results on May 8th. Dish Network (NASDAQ: DISH) shares gained 1.97% to reach a new 52-week high of $39.77. Sprint Nextel's (NYSE: S) board formed a special committee to review...
-
Neurocrine Biosciences Commences Phase IIB Study of Elagolix in Uterine Fibroids
Wednesday, March 27, 2013 - 7:20am | 236Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist, in development by AbbVie for the treatment of uterine...
-
Earnings Scheduled For March 26, 2013
Tuesday, March 26, 2013 - 4:06am | 364The Children's Place Retail Stores (NASDAQ: PLCE) is estimated to report its Q4 earnings at $1.04 per share on revenue of $496.04 million. SAIC (NYSE: SAI) is projected to post its Q4 earnings at $0.52 per share on revenue of $2.71 billion. Landec (NASDAQ: LNDC) is expected to post its Q3...